NeoGenomicsNEO
Market Cap: $2.06B
About: NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Employees: 2,100
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
273% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $2.74M
1% less funds holding
Funds holding: 259 [Q1] → 257 (-2) [Q2]
6% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 34
2.93% less ownership
Funds ownership: 101.44% [Q1] → 98.5% (-2.93%) [Q2]
14% less capital invested
Capital invested by funds: $2.03B [Q1] → $1.74B (-$290M) [Q2]
21% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 90
40% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 3 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Stephens & Co. Mason Carrico 68% 1-year accuracy 15 / 22 met price target | 18%upside $19 | Overweight Reiterated | 30 Jul 2024 |
Benchmark Bruce Jackson 27% 1-year accuracy 13 / 48 met price target | 12%upside $18 | Buy Reiterated | 30 Jul 2024 |
Needham Mike Matson 64% 1-year accuracy 72 / 113 met price target | 18%upside $19 | Buy Reiterated | 30 Jul 2024 |